GlassScriptPhysician profile
Marwan O Kaskas
NPI 1831184407
$18,441.87
in general payments reported to CMS, 2019-2025
43 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $805 · 2021: $9,555 · 2022: $1,335 · 2023: $2,205 · 2024: $1,837 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,046 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $975 · Education: $230 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,046.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $975.00 |
| Education | $229.71 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $9,308.82 | 2020-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $1,812.41 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,082.18 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $866.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $682.18 | 2019-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $602.23 | 2019-2024 | Auryxia, Vafseo |
| Amgen INC. | $562.90 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Opko Pharmaceuticals, LLC | $465.37 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $345.20 | 2021-2025 | |
| Travere Therapeutics, INC. | $325.35 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $283.91 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $245.13 | 2024-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $203.87 | 2019-2023 | Injectafer |
| Genzyme Corporation | $201.02 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $189.91 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.85 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $170.92 | 2019 | |
| Horizon Therapeutics Plc | $158.30 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $95.15 | 2021-2025 | Ultomiris |
| Shire North American Group INC | $79.99 | 2019 | |
| Novo Nordisk INC | $77.31 | 2023-2025 | Rybelsus, Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $73.92 | 2024-2025 | Jynarque |
| Nxstage Medical, INC. | $65.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $60.59 | 2022-2024 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $60.39 | 2021-2022 | |
| Veloxis Pharmaceuticals, INC. | $57.16 | 2019-2025 | Envarsus |
| Janssen Pharmaceuticals, INC | $49.85 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $40.80 | 2022-2024 | Crysvita |
| Ardelyx, INC. | $38.07 | 2025 | Ibsrela |
| Medtronic, INC. | $24.39 | 2025 | Symplicity G3 |
| Scpharmaceuticals INC. | $18.67 | 2025 | |
| Amag Pharmaceuticals, INC. | $18.13 | 2019 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Kaskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.